Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer (TNBC) accounts for about 20% of clinical breast cancer.
Clinical characteristics include early onset, high malignancy and heterogeneity. There is no
effective drug target for TNBC, resulting in poor outcomes, high relapse rate and distant
metastasis. So, further research on TNBC pathological features is particularly important.
Compared with the solvent-based paclitaxel, albumin-bound paclitaxel (nab-P) demonstrates a
stronger therapeutic effect. With albumin nanoparticles as a carrier, nab-P increases the
concentration of extra-tumor drugs by passing through the albumin receptor (Gp60)
transmembrane pathway and the secreted protein acidic and rich in cysteine (SPARC) approach
that binds to the extracellular matrix of the tumor. Numerous clinical trials have found that
nab-P is superior to the solvent-based paclitaxel in the treatment of breast cancer,
especially in breast cancer with poor prognosis. However, the current efficacy of nab-P in
the treatment of TNBC has not been fully verified. The mechanism underlying the killing
effect of nab-P on TNBC breast cancer cells remains unclear yet. This trial will compare the
therapeutic effect of nab-P with solvent-based paclitaxel in TNBC patients, and seek for
important scientific clues, scientific evidence, and clinical data for nab-P in the treatment
of TNBC.